home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Courses and Workshops  
 

European Regulatory Procedures - Comprehensive Overview of EMA and National Requirements

 
  March 28, 2016  
     
 
Center for Professional Innovation & Education, Inc., Malvern, PA
June 9 & 10, 2016


This course will give participants the necessary overview of the application procedures and regulatory filing pathways used within Europe to grant marketing authorisations for medicinal products, and of the agencies and institutions that control the regulatory process.  Special focus will be given to the European Medicines Agency (EMA) and the Centralised Procedure (CP), with the role of the national health authorities and other EU bodies in the Mutual Recognition Procedure (MRP) and Decentralised Procedure (DCP) explained also.  Factors affecting the choice of procedure will be discussed, as well as best practice in the management of the procedures.

The course will outline how variations to the marketing authorisation, as well as authorisation of specific groups of products such as orphan, paediatric, advanced therapy and herbal medicinal products are handled in the EU.  The transparency of EU regulatory decision making will be demonstrated via review and navigation of EU regulatory websites.  Key differences between FDA and EU application dossiers will be highlighted, as well as examples of common filing deficiencies from the regulator’s perspective and how to avoid them.  The impact of key emerging trends already affecting or likely to impact on regulatory filing requirements in the future will be discussed.

 
 
Organized by: Center for Professional Innovation & Education
Invited Speakers:

Mary Rafter is a pharmaceutical professional with experience across regulatory affairs, regulation of medicines, quality and scientific support. She is currently a consultant contributing to academic education programs.

Following a period in pharmaceutical quality control for Rice Steele & Co., Ms. Rafter joined the National Drugs Advisory Board (forerunner of the Irish Medicines Board) in 1983. There, she spent fourteen years as a pharmaceutical assessor. In this role, she was involved in clinical trials and the quality assessment of EU and national applications. In that time, she also developed a specialization in inhaler technologies.

In other roles, Ms. Rafter served as Technical and Marketing Services Manager for Cahill May Roberts, EU-Qualified Person in batch release with Wyeth and as Senior Regulatory Affairs Manager for Pfizer (formerly Wyeth Medica Ireland). There, her responsibilities included scientific support, training and coordination of several major regulatory projects.

She received her Bachelor of Science Degree in Pharmacy from University College Dublin and her Master's of Science Degree in Pharmaceutical Medicine from Trinity College. She also maintains her status as a registered pharmacist with the Pharmaceutical Society of Ireland.

Ms. Rafter has represented the Irish Medicines Board at CPMP/CHMP/EMEA as a pharmaceutical expert. She was also a delegate to the EU Working Party on Strategy for CFC Inhaler Phase-out and member of the EU Working Group on the Implementing Guidelines for Clinical Trials Directive.

 
Deadline for Abstracts: n/a
 
Registration: CLICK HERE TO REGISTER
E-mail: info@cfpie.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.